Javelin Pharmaceuticals Inc.

(Public, AMEX:JAV)

The follow article has been submitted to StocksHaven Investments by Nicholas DeCesare, a highly respected investor and journalist within the biopharma realm.

Take one look at a chart of Javelin Pharmaceuticals over the past six months and you will see a stock that has doubled in price but still sits only around $2.00 per share.  In fact, just two years ago, the stock was being recommended by analysts with its stock price hovering around $7.00.  In short, as detailed on their website, Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and under-served medical need in the pain management market.  Javelin’s focus is different than other pharmaceutical companies’ pain management products: they develop new and proprietary administration routes for well-characterized molecules

Below are companies with market caps under $250 million from the BioMedReports.com FDA Calendar, which have either pending FDA decisions or pending clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.

BioMimetic Therapeutics [BMTI: 9.07, -0.52 (-5.42%)]: On 6/17/09, BMTI announced that it has submitted both the pre-clinical pharmacology/toxicology and quality/manufacturing modules of its Premarket Approval (PMA) application for marketing of Augment Bone Graft